echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > GlaxoSmithKline first-in-class antibiotics apply for clinical application in China

    GlaxoSmithKline first-in-class antibiotics apply for clinical application in China

    • Last Update: 2021-12-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Rubik's Cube Info

    Author: Shi Bei

    On November 11, the CDE official website showed that the clinical application of GSK's new antibiotic Gepotidacin tablets was accepted by the State Food and Drug Administration


    Gepotidacin is a first-in-class triazapyrene type II topoisomerase inhibitor.


    Gepotidacin structure

    In foreign countries, GSK has launched a Phase III clinical project of Gepotidacin for the treatment of uncomplicated urinary tract infections (uUTI) in October 2019


    The second study (EGEL-2) was carried out in approximately 1,200 patients with uUTI.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.